Betta Pharma eyes Hong Kong listing
China-based Betta Pharmaceuticals, a developer of cancer treatments, is planning a Hong Kong IPO, having filed draft paperwork with the city’s stock exchange on Monday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: